Tags

Type your tag names separated by a space and hit enter

Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides.
Br J Dermatol. 2006 Mar; 154(3):519-23.BJ

Abstract

BACKGROUND

Psoralen plus ultraviolet (UV) A (PUVA) is the standard treatment for early stage mycosis fungoides (MF). When 8-methoxypsoralen (8-MOP) is used in PUVA therapy, it often produces intolerance reactions such as nausea, vomiting and headache.

OBJECTIVES

To investigate whether 5-methoxypsoralen (5-MOP) is a safe and effective alternative to 8-MOP in PUVA therapy for MF.

METHODS

A retrospective database search and chart review was done to identify patients with MF who received PUVA with either 5-MOP or 8-MOP as initial monotherapy at our institution. Between 1990 and 2004, 14 patients [seven men and seven women; mean age 70 years, range 51-82; National Cancer Institute disease stages IA (n = 6) and IB (n = 8)] received 5-MOP, and 24 patients [21 men and three women; mean age 58 years, range 28-89; disease stages IA (n = 11), IB (n = 12) and IIB (n = 1)] received 8-MOP.

RESULTS

Twelve of 14 patients (86%) in the 5-MOP group and 22 of 24 (92%) in the 8-MOP group had a complete response to PUVA. These two subgroups of complete responders did not differ significantly in terms of PUVA therapy duration, number of treatments or cumulative UVA dose. They also did not differ significantly in terms of relapse-free rate [8% (one of 12) vs. 23% (five of 22)] or time to relapse [17 months (range 4-31) vs. 14 months (range 4-33)]. Moreover, PUVA maintenance therapy with either 5-MOP or 8-MOP in a subset of patients [26% (nine of 34)] did not affect long-term relapse-free status either.

CONCLUSIONS

5-MOP and 8-MOP have comparable therapeutic efficacy when used in PUVA therapy for MF.

Authors+Show Affiliations

Photodermatology Unit, Department of Dermatology, Medical University Graz, Austria.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16445785

Citation

Wackernagel, A, et al. "Efficacy of 8-methoxypsoralen Vs. 5-methoxypsoralen Plus Ultraviolet a Therapy in Patients With Mycosis Fungoides." The British Journal of Dermatology, vol. 154, no. 3, 2006, pp. 519-23.
Wackernagel A, Hofer A, Legat F, et al. Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides. Br J Dermatol. 2006;154(3):519-23.
Wackernagel, A., Hofer, A., Legat, F., Kerl, H., & Wolf, P. (2006). Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides. The British Journal of Dermatology, 154(3), 519-23.
Wackernagel A, et al. Efficacy of 8-methoxypsoralen Vs. 5-methoxypsoralen Plus Ultraviolet a Therapy in Patients With Mycosis Fungoides. Br J Dermatol. 2006;154(3):519-23. PubMed PMID: 16445785.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides. AU - Wackernagel,A, AU - Hofer,A, AU - Legat,F, AU - Kerl,H, AU - Wolf,P, PY - 2006/2/1/pubmed PY - 2006/7/22/medline PY - 2006/2/1/entrez SP - 519 EP - 23 JF - The British journal of dermatology JO - Br J Dermatol VL - 154 IS - 3 N2 - BACKGROUND: Psoralen plus ultraviolet (UV) A (PUVA) is the standard treatment for early stage mycosis fungoides (MF). When 8-methoxypsoralen (8-MOP) is used in PUVA therapy, it often produces intolerance reactions such as nausea, vomiting and headache. OBJECTIVES: To investigate whether 5-methoxypsoralen (5-MOP) is a safe and effective alternative to 8-MOP in PUVA therapy for MF. METHODS: A retrospective database search and chart review was done to identify patients with MF who received PUVA with either 5-MOP or 8-MOP as initial monotherapy at our institution. Between 1990 and 2004, 14 patients [seven men and seven women; mean age 70 years, range 51-82; National Cancer Institute disease stages IA (n = 6) and IB (n = 8)] received 5-MOP, and 24 patients [21 men and three women; mean age 58 years, range 28-89; disease stages IA (n = 11), IB (n = 12) and IIB (n = 1)] received 8-MOP. RESULTS: Twelve of 14 patients (86%) in the 5-MOP group and 22 of 24 (92%) in the 8-MOP group had a complete response to PUVA. These two subgroups of complete responders did not differ significantly in terms of PUVA therapy duration, number of treatments or cumulative UVA dose. They also did not differ significantly in terms of relapse-free rate [8% (one of 12) vs. 23% (five of 22)] or time to relapse [17 months (range 4-31) vs. 14 months (range 4-33)]. Moreover, PUVA maintenance therapy with either 5-MOP or 8-MOP in a subset of patients [26% (nine of 34)] did not affect long-term relapse-free status either. CONCLUSIONS: 5-MOP and 8-MOP have comparable therapeutic efficacy when used in PUVA therapy for MF. SN - 0007-0963 UR - https://www.unboundmedicine.com/medline/citation/16445785/Efficacy_of_8_methoxypsoralen_vs__5_methoxypsoralen_plus_ultraviolet_A_therapy_in_patients_with_mycosis_fungoides_ L2 - https://doi.org/10.1111/j.1365-2133.2005.07008.x DB - PRIME DP - Unbound Medicine ER -